CABA Share Price | Cabaletta Bio, Inc. Stock Analysis & Recommendation

Q: How big is Cabaletta Bio, Inc.?

Market Cap: As of Jun 18, Cabaletta Bio, Inc. has a market capitalization of 167.74 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Cabaletta Bio, Inc. reported net sales of 0.00 million and a net profit of -126.76 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 152.34 million and total assets of 188.98 million.

Q: What does Cabaletta Bio, Inc. do?

Overview: Cabaletta Bio, Inc. is a clinical stage biotechnology company focused on the discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -36 Million (Quarterly Results - Mar 2025) Market cap: USD 167.74 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.93 Return on Equity: -104.28% Price to Book: 1.38Contact Details: Address: 2929 Arch St Ste 600, PHILADELPHIA PA: 19104-2857 Tel: 1 267 7593100 Fax: 1 302 6555049 Website: https://www.cabalettabio.com/

Q: Is Cabaletta Bio, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Cabaletta Bio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook and the KST showing a mildly bearish signal on both weekly and monthly time frames. However, the weekly MACD and Dow Theory are mildly bullish, providing some counterbalance. The stock has outperformed the S&P 500 over the past week and month, with returns of 20.44% and 23.16% respectively, but has significantly underperformed over the longer terms, particularly with a 1-year return of -51.34% compared to the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.37 M

Shareholding (Sep 2025)

FII

7.90%

Held by 78 FIIs

DII

48.02%

Held by 39 DIIs

Promoter

15.85%

How big is Cabaletta Bio, Inc.?

22-Jun-2025

As of Jun 18, Cabaletta Bio, Inc. has a market capitalization of 167.74 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -126.76 million over the latest four quarters. The company reported shareholder's funds of 152.34 million and total assets of 188.98 million as of Dec 24.

View full answer

What does Cabaletta Bio, Inc. do?

22-Jun-2025

Cabaletta Bio, Inc. is a clinical stage biotechnology company focused on developing engineered T-cell therapies for B cell-mediated autoimmune diseases, with a market cap of approximately $167.74 million and a recent net profit of -$36 million.

View full answer

Who are in the management team of Cabaletta Bio, Inc.?

22-Jun-2025

As of March 2022, the management team of Cabaletta Bio, Inc. includes Dr. Steven Nichtberger as Chairman, President, CEO, and Co-Founder, along with independent directors Dr. Catherine Bollard, Dr. Brian Daniels, Mr. Richard Henriques, and Mr. Mark Simon.

View full answer

Is Cabaletta Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Cabaletta Bio, Inc. is in a mildly bearish trend, indicated by daily moving averages and KST signals, despite recent outperformance against the S&P 500, with a 1-year return of -51.34% compared to the S&P 500's 17.14%.

View full answer

Compare Cabaletta Bio, Inc. with Similar Stocks

Wave Life Sciences Ltd.Curis, Inc.Kura Oncology, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 214 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.99

Return on Equity

-113.66%

Price to Book

1.53

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-45 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

41.81%

6 Months

-12.39%

1 Year

-77.16%

2 Years

-79.34%

3 Years

110.92%

4 Years

-70.81%

5 Years

-70.68%

Cabaletta Bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-228.87%

EBIT to Interest (avg)

-71.58

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.93

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.04

EV to EBIT

-0.10

EV to EBITDA

-0.10

EV to Capital Employed

1.48

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-1505.51%

ROE (Latest)

-104.28%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 45 Schemes (28.16%)

Foreign Institutions

Held by 78 Foreign Institutions (7.9%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -63.41% vs -90.34% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-45.40",
          "val2": "-29.90",
          "chgp": "-51.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-45.10",
          "val2": "-27.60",
          "chgp": "-63.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -71.20% vs -27.74% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-120.30",
          "val2": "-73.20",
          "chgp": "-64.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-115.90",
          "val2": "-67.70",
          "chgp": "-71.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-45.40

-29.90

-51.84%

Interest

0.60

0.00

Exceptional Items

0.00

Consolidate Net Profit

-45.10

-27.60

-63.41%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -63.41% vs -90.34% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-120.30

-73.20

-64.34%

Interest

0.70

0.00

Exceptional Items

0.00

Consolidate Net Profit

-115.90

-67.70

-71.20%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -71.20% vs -27.74% in Dec 2023

All Annual Results

Company CV

About Cabaletta Bio, Inc.

Cabaletta Bio, Inc.

Pharmaceuticals & Biotechnology

Cabaletta Bio Inc. is a clinical stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company’s lead CAAR T cell product candidate are designed based on chimeric antigen receptor, and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.

Company Coordinates

Company Details

2929 Arch St Ste 600 , PHILADELPHIA PA : 19104-2857

Tel: 1 267 7593100

https://www.cabalettabio.com/

Registrar Details

Cabaletta Bio, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Cabaletta Bio, Inc.?

Watch in Real-Time

What does Cabaletta Bio, Inc. do?

Who are in the management team of Cabaletta Bio, Inc.?

Is Cabaletta Bio, Inc. technically bullish or bearish?

Compare Cabaletta Bio, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Cabaletta Bio, Inc.

Company Coordinates